Dermatología en Costa Rica

Monday, July 24, 2017

Excelente comentario, para evitar uso innecesario de antibióticos.

Just Because It's Red Doesn't Mean It's Infected!

Dear Readers,

Cellulitis is a bacterial infection of the skin frequently encountered in patients seen in a wound center. Erysipelas, although slightly different, is a similar skin infection,[1] but for the most part is considered to be a type of cellulitis with similar etiologies and similar treatments. These diagnoses accounted for about 10% of hospital admissions related to infection from 1998 to 2006.[2] The cost to treat cellulitis in the United States in 2006 was about $3.7 billion.[3] A recent report in the literature suggests that our ability to correctly diagnosis cellulitis is greatly overestimated.[4] The study showed that in a large Boston hospital from June 2010 to December 2012, 259 patients were admitted with a diagnosis of lower extremity cellulitis. By the time of discharge, 30.5% of patients were found to have been misdiagnosed as having cellulitis. Of the group who were misdiagnosed, 84.6% were found to have not needed hospitalization at all and 92.3% received unnecessary antibiotics.[4] In addition to the huge financial waste, the potential for causing harm with unnecessary antibiotics — mostly intravenously administered — existed. Complications associated with providing intravenous access either peripherally or centrally can be significant. The antibiotic therapy itself can also cause problems such as anaphylaxis or other reactions and Clostridium difficile colitis.

What, if anything, can we do to minimize the misdiagnosis of cellulitis? Unfortunately, not a lot of help is available. The clinical presentation of these patients usually involves a warm, painful, red, swollen extremity.[5] One positive finding with cellulitis is that it is usually unilateral. Occasionally, the patients will have a history of a comorbidity such as diabetes mellitus. The risk factor most commonly associated with cellulitis is edema or lymphedema.[5] This is because lymphatic fluid with its elevated protein content facilitates bacterial growth.[5]There are numerous laboratory tests that are routinely done in patients suspected of having cellulitis but none, including blood cultures, are considered specific to cellulitis. Cultures of the leg either with the swab technique, needle aspiration of fluid from the subcutaneous tissues, or even biopsy of the tissue are not recommended because the yield is so low.[1] In addition, imaging studies are not helpful to diagnosis cellulitis but may help rule out an abscess or necrotizing fasciitis.[5]

If it isn't cellulitis, then what could it be? One of the most common problems we see mimicking cellulitis is dependent rubor, which is seen in patients with peripheral neuropathy and ischemic vascular disease. When the extremity is dependent, the microcirculation is disordered, resulting in a red discoloration. Depending on the severity of the condition, the redness can extend from the toes to the knee. Many times this redness is bilateral. Simply elevating the leg can make the diagnosis; if the redness is the result of neuropathy or ischemia, it will resolve, whereas the redness due to cellulitis will not. Venous stasis dermatitis is commonly mistaken for cellulitis.[6] Other lower extremity inflammatory conditions such as an acute Charcot joint, gout, and other dermatologic conditions can be mistaken for cellulitis.[4,5]

If an infectious etiology is confirmed, antibiotics are definitely indicated, but there is little consensus on the appropriate antibiotic regimen.[5,7] It is felt that treatment of the edema and lymphedema fluid in the leg with compression therapy will make any antibiotic regimen more effective and speed the resolution of the infection and inflammatory reaction.[8] Another common conclusion is that most of these patients with suspected cellulitis could be treated without hospitalization even if the patient does have cellulitis; unless the patient is septic or significantly immunocompromised, outpatient treatment is being recommended.[9,10]

With all this information in mind, it's time we rethink our approach to the red leg. It's obvious that all red legs are not infected and that careful evaluation and treatment of these patients are needed to provide not only the appropriate therapy but also safe, cost-effective therapy.


Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
4000-1054
2208-8206
Please excuse the shortness of this message, as it has been sent from a mobile device.

Thursday, July 20, 2017

Aceite esencial de arbol de Te (M. alternifolia) es un contactante imporante...

Patch-Test Reactions to Essential Oils Evaluated

Dermatitis; ePub 2017 Jun 13; Warshaw, et al

Testing to essential oils (EOs) may be important for detecting allergic sensitivity not detected by fragrance markers (FMs) alone, according to a recent study. This study used a retrospective analysis of patch-test results and relevant demographic/clinical data collected electronically. Researchers found:

  • Overall, 62,354 patients were tested to 3 FMs and EOs; 11,568 (18.6%) reacted to at least 1 FM or EO, whereas 857 (1.4%) reacted to 1 or more EOs but none of the 3 FMs.
  • For both the US/Canadian and Central European groups, individuals who were positive to 1 or more of the 9 study allergens were significantly less likely to be male, have occupational skin disease, or have hand involvement and significantly more likely to have leg dermatitis and be ≥40 years.
  • Of the 140 US/Canadian patients who reacted to 1 or more of the 5 EOs but none of the FMs, M. alternifolia yielded most positive reactions (45%); half of these reactions were strong and of definite/probable clinical relevance (52.4%).
Citation:

Warshaw EM, Zug KA, Belsito DV, et al. Positive patch-test reactions to essential oils in consecutive patients: Results from North America and Central Europe. [Published online ahead of print June 13, 2017]. Dermatitis. doi:10.1097/DER.0000000000000293.

Estudio quirúrgico en Hidradenitis Suppurativa... 35 años.

35-Year Evaluation of Surgical Treatment for HS

World J Surg; ePub 2017 Jun 13; Burney 

Surgical treatment of hidradenitis suppurativa (HS) by wide local excision with healing by secondary intention using tap water-moistened plain gauze dressings changed 2 to 3 times per day is a simple, practical approach that has good results, a recent study found. Researchers conducted a retrospective review of all patients operated on for HS over a 35-year period. Specific data abstracted included patient age, weight, admission, length of stay, wound size, type of wound care, number of post-op visits, time to heal, and recurrence. They found:

  • From 1979 through 2014, 122 patients (56 men and 66 women, median age 38), underwent 245 operations for HS.
  • Patients underwent from 1 to 10 procedures; 61 patients (50%) underwent ≥2 procedures; and 26 (21%) underwent ≥3.
  • Wound sizes at operation ranged from quite small to >1,500 cm2.
  • A total of 197 wounds healed by secondary intention: 83 of these were left completely open at the time of surgery; 117 were partially closed.
  • In total, 106 procedures were ambulatory; median wound size was 30 cm2; and median time to heal was 40 days.
Citation:

Burney, RE. 35-year experience with surgical treatment of hidradenitis suppurativa. [Published online ahead of print June 13, 2017]. World J Surg. doi:10.1007/s00268-017-4091-7.

Oxido de Zinc util en heridas... un viejo conocido.

Zinc Oxide Gets High Marks for Wound Care

Dermatol Surg; ePub 2017 Jun 23; Thompson, et al

Zinc oxide compression dressing is a practical option for postoperative wound care, with decreased incidence of delayed wound healing, and fewer complications vs standard postoperative wound dressing, according to a recent study. In this retrospective cohort study, healing time and complication rate of 44 patients treated with standard dressing and 36 patients treated with zinc oxide compression dressing were compared. Researchers found:

  • At 19 days, 91.7% of patients receiving zinc oxide dressing were fully healed, whereas only 65.9% of patients receiving standard wound care were healed.
  • Complications were noted in 6 of the patients receiving standard dressing (13.6%); no complications occurred in the zinc oxide dressing group.
Citation:

Thompson C, Wiemken TL, Brown TS. Effect of postoperative dressing on excisions performed on the leg: A comparison between zinc oxide compression dressing versus standard wound care. [Published online ahead of print June 23, 2017]. Dermatol Surg. doi:10.1097/DSS.0000000000001209.

Será que el estudio de Ig E específicos ayude en el tratamiento y control de pacientes con Dermatitis Atópica?

Allergen Identification Improves AD Outcomes

Int J Dermatol; ePub 2017 Jun 20; Will, et al

Knowledge of identified specific antigens can guide patients to make lifestyle modifications that may improve disease outcomes in atopic dermatitis (AD), a recent study found. Immunoglobulin E (IgE) quantitative assaying of allergens (IgEQAA) and avoidance of allergens may help some patients with AD. IgEQAA has long been implemented by allergists in determining patients' reactivities for allergic rhinitis and asthma, 2 of the 3 diagnoses in atopic syndrome. In this study, the affected body surface area (BSA) at first presentation, IgEQAA classes, and total IgE concentration were taken retrospectively for 54 patients with AD. Researchers found:

  • Of the 54 patients observed, 41 had an abnormally high total IgE concentration (76%).
  • Additionally, it was observed that 9 (17%) patients significantly improved after making lifestyle changes.
Citation:

Will BM, Severino R, Johnson DW. Identification of allergens by IgE-specific testing improves outcomes in atopic dermatitis. [Published online ahead of print June 20, 2017]. Int J Dermatol. doi:10.1111/ijd.13673.

Enfermedad de Parkinson incrementa el Riesgo de padecer, Melanoma!

Association Between Melanoma and Parkinson Disease

Mayo Clin Proc; 2017 Jul; Dalvin, Damento, et al

There appears to be an association between melanoma and Parkinson disease (PD), according to a recent study. Therefore, physicians may consider counseling patients with melanoma about PD risk and implementing cutaneous and ocular melanoma surveillance in patients with PD. The cohort consisted of 2 phases. Phase I: Rochester Epidemiology Project records were used to identify (between January 1, 1976, and December 31, 2013) patients with PD in Olmsted County, MN, with 3 matched controls per case. Phase II: All Rochester Epidemiology Project cases of melanoma were identified (between January 1, 1976, and December 31, 2014), with 1 control per case. Researchers found:

  • Phase I: Patients with PD had a 3.8-fold increased likelihood of having preexisting melanoma as compared with controls.
  • Phase II: Patients with melanoma had a 4.2-fold increased risk of developing PD.
  • Kaplan-Meier analysis revealed an increased 35-year cumulative risk of PD in patients with melanoma (11.8%) compared with controls (2.6%).
  • Patients with melanoma without PD had a 10.5-fold increased relative risk of death from metastatic melanoma compared with patients with melanoma with PD.
Citation:

Dalvin LA, Damento GM, Yawn BP, et al. Parkinson disease and melanoma. Confirming and reexamining an association. Mayo Clin Proc. 2017;92(7):1070-1079. doi:10.1016/j.mayocp.2017.03.014.

Citometría de Flujo y PCR por rearreglo del TCR en sangre, son importantes para la detección del Síndorme de Sézary en forma temprana.

Nonerythrodermic Dermatitis and Early Sézary Syndrome

J Am Acad Dermatol; ePub 2017 Jul 11; Mangold, et al

Erythroderma is uncommon as an initial sign of Sézary syndrome (SS), according to a recent study. Therefore, early SS should be considered in cases of nonerythrodermic dermatitis that is refractory to conventional treatments. In these cases, examination of the blood by PCR for monoclonal T-cell receptor rearrangement and by flow cytometry to identify an expanded or aberrant T-cell population should be considered. A retrospective, multicenter chart review was performed for 263 confirmed cases of SS diagnosed during 1976-2015. Researchers found:

  • Erythroderma was the earliest recorded skin sign of SS in only 25.5% of cases, although most patients (86.3%) eventually developed erythroderma.
  • In patients without erythroderma during their initial visit, the first cutaneous signs of SS were nonspecific dermatitis (49%), atopic dermatitis-like eruption (4.9%), or patches and plaques of mycosis fungoides (10.6%).
  • The mean diagnostic delay was 4.2 years overall, 2.2 years for cases involving erythroderma at the initial presentation, and 5.0 years for cases not involving erythroderma at the initial presentation.
Citation:

Mangold AR, Thompson AK, Davis MD, et al. Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study. [Published online ahead of print July 11, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.05.036.

Interesante: CD4 es determinante en la prevalencia de Carcionoma Epidermoide en Pacientes con HIV.

Persons Infected with HIV at Higher Risk for New SCC

JAMA Dermatol; ePub 2017 Jul 12; Asgari, Ray, et al

HIV-infected persons compared with HIV-uninfected persons were at higher risk for subsequent new squamous cell carcinoma (SCC) but not basal cell carcinoma (BCC), with a dose-response relationship between risk and lower CD4 counts and higher viral loads (VLs), a recent study found. This cohort study analyzed 455 HIV-infected and 1,945 HIV-uninfected patients, all of them members of the Kaiser Permanente Northern California health care plan, diagnosed with at least 1 nonmelanoma skin cancer (NMSC) from 1996-2008 to determine risk of subsequent NMSCs in relation to CD4 count and VL. Researchers found:

  • Compared with HIV-uninfected persons, HIV-infected individuals were slightly younger (mean age, 52.5 vs 55.5 years), more likely men (97% vs 92%), more likely to have smoked (57% vs 45%), and less likely to be overweight/obese (50% vs 61%).
  • Compared with uninfected individuals, those with HIV infection with a recent biomarker of more severe immune deficiency (CD4 count <200 cells/mL) had a 44% increased risk of subsequent NMSC overall and a 222% increase risk of SCC in particular, suggesting that subsequent SCC risk is associated with immune dysfunction.
Citation:

Asgari MM, Ray GT, Quesenberry Jr CP, Katz KA, Silberberg MJ. Association of multiple primary skin cancers with human immunodeficiency virus infection, CD4 count, and viral load. [Published online ahead of print July 12, 2017]. JAMA Dermatol. doi:10.1001/jamadermatol.2017.1716.

Interesante estudio observaciones de ingesta de litio y reducción de melanoma, el problema son los efectos adversos!

Lithium May Reduce Melanoma Risk, Mortality

J Invest Dermatol; ePub 2017 Jun 16; Asgari, et al

Lithium may reduce melanoma risk and associated mortality, according to a recent study. Researchers conducted a retrospective cohort study of adult white Kaiser Permanente Northern California members (n=2,213,848) from 1997-2012 to examine the association between lithium use and melanoma risk. Lithium exposure (n=11,317) was assessed from pharmacy databases, serum lithium levels were obtained from electronic laboratory databases, and incident cutaneous melanomas (n=14,056) were identified from an established cancer registry. They found:

  • Melanoma incidence per 100,000 person-years among lithium-exposed individuals was 67.4, compared to 92.5 in unexposed individuals.
  • Lithium-exposed individuals had a 32% lower risk of melanoma risk in unadjusted analysis, but the estimate was attenuated and non-significant in adjusted analysis.
  • No lithium-exposed individuals presented with thick (>4 mm) or advanced-stage melanoma at diagnosis.
  • Among melanoma cases, lithium-exposed individuals were less likely to suffer melanoma-associated mortality (rate=4.68/1,000 person years) as compared to the unexposed (rate=7.21/1,000 person-years).
Citation:

Asgari MM, Chien AJ, Tsai AL, Fireman B, Quesenberry Jr CP. Association between lithium use and melanoma risk and mortality: A population-based study. [Published online ahead of print June 16, 2017]. J Invest Dermatol. doi:10.1016/j.jid.2017.06.002.

Teledermatología es una buena opción ante las dificultades de movilidad en nuestro país.

Teledermatology and Face-to-Face Consults Compared

Int J Dermatol; ePub 2017 Jun 20; Creighton-Smith, et al

Face-to-face (F2F) consultation patients were more likely to have prior history of skin cancer and receive biopsies than store-and-forward (SAF) teledermatology patients, a recent study found. This retrospective cohort study compared patient skin cancer risk profile, pre-post biopsy diagnostic accuracy, and detection rates of any skin cancer, melanoma, and keratinocytic carcinoma between all SAF teledermatology patients and a subset of randomly selected F2F consultations at VA-Boston Healthcare System in 2014. Researchers found:

  • Patients in the teledermatology (n=434) and F2F visit cohorts (n=587) had similar baseline demographics except a higher proportion of F2F patients had prior history of skin cancer, 22% (131/587) vs 10% (45/434), and received biopsies, 27.2% (160/587) vs 11.5% (50/434).
  • When adjusted for age, immunosuppression, and personal and family history of skin cancer, there were no significant differences between the 2 cohorts in detection rates for any skin cancer (9.5% vs.5.8%), melanoma (0.6% vs 0%), or keratinocytic carcinoma (8.5% vs 5.5%).
Citation:

Creighton-Smith M, Murgia III RD, Konnikov N, Dorneles, Garber C, Nguyen BT. Incidence of melanoma and keratinocytic carcinomas in patients evaluated by store-and-forward teledermatology vs dermatology clinic. [Published online ahead of print June 20, 2017]. Int J Dermatol. doi: 10.1111/ijd.13672.

Como evitar restistencia antibiótica en Acne...

Guidelines: Antibiotic Resistance in Acne Treatment

JAMA Dermatol; ePub 2017 Jun 21; Adler, et al

The American Academy of Dermatology's most recent guidelines for acne treatment recommend co-administration of benzoyl peroxide (BP), a topical bactericidal agent not reported to cause resistance, alongside both topical and oral antibiotics. BP is comedolytic and kills Propionibacterium acnes by generating free radicals. These guidelines recommend resistance reduction strategies, including avoidance of antibiotic monotherapy, combination treatment with topical modalities, and limiting the duration of oral antibiotic use. Highlights are as follows:

  • For mild-to-moderate acne, first-line treatment is with BP, topical retinoids, or combination therapy, which may incorporate a topical antibiotic (BP + antibiotic, BP + retinoid, BP + antibiotic + retinoid). Topical antibiotic monotherapy is not recommended. In patients who benefit from topical antibiotic treatment, available fixed-combination antibiotic/BP formulations simplify the regimen and potentially improve patient adherence.
  • For moderate-to-severe acne, first-line treatment is with oral antibiotics combined with BP and a topical retinoid. Oral antibiotic monotherapy is not recommended. Topical antibiotics may also be included in the regimen, provided BP is used concomitantly.
  • The first-line oral antibiotics are doxycycline and minocycline, which exert anti-inflammatory as well as antimicrobial effects.
  • Because of associated resistance, systemic erythromycin should be avoided, except in patients unable to tolerate tetracycline therapy (eg, pregnant women and children aged <8 years); trimethoprim-sulfamethoxazole may also be considered.
  • Duration of therapy should preferably be limited to 3 to 4 months. To facilitate this, BP and topical retinoids should be continued as maintenance therapy after discontinuation of systemic antibiotic treatment.
Citation:

Adler BL, Kornmehl H, Armstrong. Antibiotic resistance in acne treatment. [Published online ahead of print June 21, 2017]. JAMA Dermatol. doi:10.1001/jamadermatol.2017.1297.

Riesgo de padecer rosacea se mantiene a pesar de dejar de fumar...Mejor No fumar...

Rosacea Risk Persists Among Former Smokers

Am J Epidemiol; ePub 2017 May 3; Li, et al

The risk of rosacea was significantly increased within 3 to 9 years since smoking cessation, and the significant association persisted among past smokers who had quit for >30 years, a recent study found. In order to determine the association between smoking and risk of incident rosacea, researchers included 95,809 women from Nurses' Health Study II (1991–2005). Information on smoking was collected biennially during follow-up; information on history of clinician-diagnosed rosacea and year of diagnosis was collected in 2005. They found:

  • During the follow-up, 5,462 incident cases of rosacea were identified.
  • Compared with never smokers, there was an increased risk of rosacea associated with past smoking but a decreased risk of rosacea associated with current smoking.
  • Increasing pack-years of smoking was also associated with an elevated risk of rosacea among past smokers, and was associated with a decreased risk of rosacea among current smokers.
Citation:

Li S, Cho E, Drucker AM, Qureshi AA, Li W-Q. Cigarette smoking and risk of incident rosacea in women. [Published online ahead of print May 3, 2017]. Am J Epidemiol. doi:10.1093/aje/kwx054.

Prevalencia de Hidradenitis Suppurativa, estudiada en USA.

Prevalence of HS in General Population Analyzed

JAMA Dermatol; ePub 2017 May 10; Garg, et al

Hidradenitis suppurativa (HS) is an uncommon disease in the US that disproportionately affects female patients, young adults, and African American and biracial patients, according to a recent study. This retrospective analysis included a demographically heterogeneous population-based sample of >48 million unique patients across all US census regions. A total of 47,690 patients with HS were identified using electronic health record data. Researchers found:

  • Of total patients with HS (26.2% men and 73.8% women), the overall HS prevalence in the US population sample was 0.10%, or 98 per 100,000 persons.
  • The adjusted prevalence in women was 137 per 100,000, more than twice that of men (58 per 100,000).
  • The prevalence of HS was highest among patients aged 30 to 39 years (172 per 100,000) compared with all other age groups (range, 15-150 per 100,000).
  • Adjusted HS prevalence among African American (296 per 100,000) and biracial (218 per 100,000) patients were more than 3-fold and 2-fold greater, respectively, than that among white patients (95 per 100,000).
Citation:

Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. [Published online ahead of print May 10, 2017]. JAMA Dermatol. doi:10.1001/jamadermatol.2017.0201.

Contactantes prevalentes en muchos productos de uso diario causan epidemia en USA y testeo debe mejorar.

Isothiazolinone Allergy Epidemic in North America

Dermatitis; ePub 2017 May 1; Zirwas, et al

The epidemic of isothiazolinone sensitivity documented in Europe is now in North America, according to a recent study. During the last decade, the use of methylisothiazolinone (MI) at higher concentrations in both leave-on and rinse-off products has significantly increased. Furthermore, patch testing with only methylchloroisothiazolinone (MCI)/MI 0.01% aqueous (aq) will miss approximately half of isothiazolinone allergy cases, whereas testing with only MI 0.2% aq will miss approximately 10% of isothiazolinone allergy cases. At 13 centers in North America, 4,860 patients were patch tested in a standardized manner with a series of 70 allergens, including MCI/MI 0.01% aq and MI 0.2% aq. Researchers found:

  • 305 patients (6.3%) had a positive reaction to MCI/MI; this is a significant increase from the previous cycle (5.0%, 2011-2012).
  • 521 patients (10.7%) had a positive reaction to MI.
  • These 2 isothiazolinones were among the most common preservative allergens in the 2013 to 2014 cycle; 11.9% of patch-tested individuals were allergic to 1 or both isothiazolinones.
  • Individuals with MCI/MI and MI allergy were significantly more likely to have occupationally related skin disease and hand dermatitis.
Citation:

Zirwas MJ, Hamann D, Warshaw EM, et al. Epidemic of isothiazolinone allergy in North America: Prevalence data from the North American Contact Dermatitis Group, 2013-2014. [Published online ahead of print May 1, 2017]. Dermatitis. doi:10.1097/DER.0000000000000288.

Transplante de Melanocitos y Queratinocitos demostró beneficio en leucodermias.

MKTP Procedure Satisfactory for Leukoderma Treatment

J Am Acad Dermatol; ePub 2017 May 11; Silpa-Archa, et al

The melanocyte-keratinocyte transplantation procedure (MKTP) provides satisfactory long-term repigmentation in the majority of appropriately selected patients with leukoderma, according to a recent study. Furthermore, MKTP can maintain repigmentation for at least 72 months. Researchers performed a retrospective review of electronic medical records for all MKTPs performed at Henry Ford Hospital between January 2009 and April 2014. Repigmentation was assessed by a 5-point grading scale (poor to excellent) and Vitiligo Area Scoring Index (VASI). They found:

  • 100 patients had MKTP performed at 236 anatomically-based lesions (ABLs); 63 patients with 157 ABLs had long-term data available (12-72 months; median, 24 months).
  • Segmental vitiligo, nonsegmental vitiligo, and physical leukoderma demonstrated improvement in VASI scores: −75.6 ± 24.6%, −59.2 ± 36.6%, and −32.4 ± 33.5%, respectively.
  • In vitiligo, at 24, 48, and 72 months after MKTP, 53%, 64%, and 53% of ABLs, respectively, maintained >75% repigmentation.
  • Skin phototype, age, and anatomic location of ABLs had no significant effect on the outcome of treatment.
Citation:

Silpa-Archa N, Griffith JL, Huggins RH, et al. Long-term follow-up of patients undergoing autologous noncultured melanocyte-keratinocyte transplantation for vitiligo and other leukodermas. [Published online ahead of print May 11, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.01.056.

Tipo de Dietas que son beneficiosas en pacientes con Psoriasis.

Dietary Behaviors of Patients with Psoriasis

Dermatol Ther; ePub 2017 May 19; Afifi, Danesh, et al

Specific diets with the most patients reporting a favorable skin response for psoriasis patients were Pagano (72.2%), vegan (70%), and Paleolithic (68.9%), according to results of a recent national survey, among the first to report the dietary behaviors of patients with psoriasis. Data provided from this large cohort may benefit patients and clinicians as they discuss the role of diet in managing both psoriasis and associated cardiometabolic comorbidities. Researchers administered a 61-question survey to the National Psoriasis Foundation membership asking psoriasis patients (n=1,206) about dietary habits, modifications, skin responses, and perceptions. They also found:

  • Compared to age- and sex-matched controls, psoriasis patients consumed significantly less sugar, whole grain fiber, dairy, and calcium, while consuming more fruits, vegetables, and legumes.
  • 86% of respondents reported use of a dietary modification.
  • The percentage of patients reporting skin improvement was greatest after reducing alcohol (53.8%), gluten (53.4%), nightshades (52.1%), and after adding fish oil/omega-3 (44.6%), vegetables (42.5%), and oral vitamin D (41%).
  • Additionally, 41.8% of psoriasis respondents reported that a motivation for attempting dietary changes was to improve overall health.
Citation:

Afifi L, Danesh MJ, Lee KM, et al. Dietary behaviors in psoriasis: Patient-reported outcomes from a US national survey. [Published online ahead of print May 19, 2017]. Dermatol Ther. doi:10.1007/s13555-017-0183-4.

Incremento de enfermedades cardio y cerebrovasculares en pacientes con enfermedades dermatológicas inflamatorias.

Inflammatory Skin Disease & CVD/Cerebrovascular Risk

Am J Clin Dermatol; ePub 2017 May 22; Kwa, et al

Psoriasis, pemphigus, bullous pemphigoid (BP), atopic dermatitis or eczema (AD-E), and hidradenitis were all associated with increased cardiovascular and cerebrovascular risk, especially at younger age, according to a recent study. Researchers analyzed data from the 2002–2012 National Inpatient Sample, including a representative 20% sample of all US hospitalizations (n=72,108,077 adults). They found:

  • In multivariate logistic regression models with propensity score matching, patients hospitalized with vs without a diagnosis of the inflammatory skin diseases examined had higher odds of obesity for pemphigus, BP, AD-E, psoriasis, and hidradenitis.
  • Inflammatory skin disease was also associated with significantly higher odds of different cardiovascular risk factors, including hypertension and diabetes mellitus with complications, as well as vascular, cardiovascular, and cerebrovascular disease, including peripheral vascular disease, peripheral and visceral atherosclerosis, pulmonary circulation disorders, congestive heart failure, history of transient ischemic attack, and cerebrovascular disease.
  • In stratified analyses, multiple inflammatory skin diseases were associated with significantly higher rates of obesity, hypertension, and/or diabetes in patients aged <50 years and females.
Citation:

Kwa MC, Silverberg JI. Association between inflammatory skin disease and cardiovascular and cerebrovascular co-morbidities in US adults: Analysis of Nationwide Inpatient Sample Data. [Published online ahead of print May 22, 2017]. Am J Clin Dermatol. doi:10.1007/s40257-017-0293-x.

Incremento incidencia SCC y BCC

Incidences of BCC and cSCC Are Increasing 

Mayo Clin Proc; ePub 2017 May 15; Muzic, et al

Incidences of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are increasing, with a disproportionate increase in cSCC relative to BCC, according to a recent study. There is also a disproportionate increase in the incidence of both tumors in women, as well as a shift of anatomical distributions. Researchers reviewed the medical records of a population-based cohort diagnosed with nonmelanoma skin cancer between January 2, 2000, and December 31, 2010. They found:

  • The age-adjusted BCC incidence (cases per 100,000 person-years) was 360.0 in men and 292.9 in women.
  • The age-adjusted cSCC incidence (cases per 100,000 person-years) was 207.5 in men and 128.8 in women.
  • From years 1976 to 1984 to years 2000 to 2010, the age- and sex-adjusted incidence (cases per 100,000 person-years) of BCC increased from 222.0 to 321.2 and that of cSCC from 61.8 to 162.5.
  • Over time, the anatomical distribution of BCC shifted from the head and neck to the torso and that of cSCC shifted from the head and neck to the extremities.
Citation:

Muzic JG, Schmitt AR, Wright AC, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma. [Published online ahead of print May 15, 2017]. Mayo Clin Proc. doi:10.1016/j.mayocp.2017.02.015.

Tuesday, July 18, 2017

Medicamentos orales para rosacea ocular... hay que volver a traer la eritromicina!

SYSTEMIC THERAPY FOR OCULAR AND CUTANEOUS ROSACEA IN CHILDREN

This retrospective study aimed to analyze children with rosacea presenting ocular symptoms, submitted to systemic treatment, particularly addressing remission and relapse rates.

Medical records of 19 children with ocular rosacea treated with a systemic antibiotic were reviewed. Of these, nine were selected for further analysis.

The results indicated that 89.5% of the children had blepharitis, 78.9% had conjunctivitis, 63.2% had a hordeolus, and 9 female patients (47.4%) had corneal involvement.

Erythromycin (n = 9) or roxithromycin (n = 1) were used in patients <8 years of age and doxycycline (n = 8) or minocycline (n = 1) in patients over 8 years of age.

The results indicated complete remission of ocular and cutaneous symptoms in 77.78% of patients who used erythromycin, 12.5% of the patients treated with doxycycline, and in the patient treated with minocycline. Partial remission occurred in 22.22% of patients treated with erythromycin, 87.5% of patients treated with doxycycline, and among the patient treated with roxithromycin. Recurrences occurred in 25% of patients treated with doxycycline (ocular and cutaneous), in patients treated with minocycline (cutaneous), and in 11.11% of patients treated with erythromycin (cutaneous).

The authors concluded that anti-inflammatory treatment of at least 6 months is necessary for complete remission of cutaneous and ocular rosacea.

J Eur Acad Dermatol Venereol. 2017 Jun 16. doi: 10.1111/jdv.14402. [Epub ahead of print]
Systemic therapy of ocular and cutaneous rosacea in children.
Gonser LI, Gonser CE, Deuter C, Heister M, Zierhut M, Schaller M.

ixekizumab sirve para ArPso en ptes que fallan a un Anti Tnf

Ixekizumab helps PsA patients who failed a TNFi

AT THE EULAR 2017 CONGRESS

MADRID – The anti–interleukin-17 drug ixekizumab, already on the U.S. market for treating psoriasis, showed efficacy and safety for treating psoriatic arthritis in patients who previously failed to respond to or tolerate a tumor necrosis factor inhibitor in a pivotal, phase 3 trial with 363 patients.

Treatment of patients with psoriatic arthritis (PsA) with ixekizumab (Taltz) led to improvements, compared with placebo, in arthritis, physical function, and psoriasis. These patients were unresponsive to or intolerant of a tumor necrosis factor inhibitor (TNFi) at rates similar to previously reported response rates for PsA patients who were TNFi naive, Peter Nash, MD, said at the European Congress of Rheumatology.

A published report with the data presented by Dr. Nash also recently appeared (Lancet. 2017;389[10086]:2317-27).

The results showed "no unexpected" safety findings, with safety profiles consistent with what has been seen in psoriasis patients and in PsA patients in a prior phase 3 study, said Dr. Nash, a rheumatologist at Queensland University in Brisbane, Australia.
Based in part on the results from this trial, as well as results from a companion phase 3 trial that enrolled PsA patients naive to a TNFi (Ann Rheum Dis. 2017 Jan; 6[1]:79-87), the company that markets ixekizumab, Eli Lilly, filed an application with the Food and Drug Administration in early 2017 to have a new label indication for PsA, said a company spokeswoman.

"At least half of PsA patients don't get at least a 20% improvement [an ACR20 response] on a TNFi, and so they are looking for something else," explained Mark C. Genovese, MD, professor of medicine and director of the Rheumatology Clinic at Stanford (Calif.) University and a coinvestigator on the trial reported by Dr. Nash. "There is pent up demand" for an alternative to a TNFi for treating PsA, Dr. Genovese said in an interview.

The primary endpoint of the Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P2) was the proportion of patients who attained at least 20% improvement in the American College of Rheumatology response criteria (ACR20) at week 24, reached by 53% of patients who received an 80 mg subcutaneous injection of ixekizumab every 4 weeks and by 20% of patients on placebo, a statistically significant difference. The finding that ixekizumab improved half the patients who failed TNFi treatment is "a tremendous opportunity" for the alternative drug class, Dr. Genovese commented.

The finding also sets ixekizumab apart from secukinumab (Cosentyx), another interleukin-17 inhibitor that already has FDA approval for treating PsA but that has not been specifically tested in PsA patients who failed or didn't tolerate a TNFi, he noted.

The SPIRIT-P2 results also showed superior outcomes for patients treated with an ixekizumab injection once every 2 or 4 weeks, compared with placebo, by several secondary measures, including ACR50 and ACR70 rates and minimal disease activity. The ACR70 rate after 24 weeks on treatment was 23% with a dose of ixekizumab every 4 weeks and none with placebo. Minimal disease activity was reached by about a quarter of patients on either dosage of the active drug and by 3% of patients on placebo.

Despite the apparent role for ixekizumab when TNFi treatment fails, the TNFi drug class remains the clear first-line choice for PsA patients who are starting a biological drug for the first time. Not only do the TNFis have a much longer and more extensive track record but they also generally receive better insurance coverage that minimizes out-of-pocket expenses for patients, Dr. Genovese said.

SPIRIT-P2 was sponsored by Eli Lilly, the company that markets ixekizumab. Dr. Nash has been a speaker for or consultant to and has received research funding from Eli Lily and for several other companies. Dr. Genovese has been a consultant to and has received research funding from Eli Lilly, AbbVie, Astellas, Galapagos, Pfizer, and Vertex.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler